Quick Answer
HAEMONETICS CORP reported Research And Development Expense of $62.72 million for the year ending 2025.
- HAEMONETICS CORP showed an increase of +15.2% in Research And Development Expense from 2024 to 2025.
- This data is from HAEMONETICS CORP's annual report (Form 10-K), filed with the SEC on May 21, 2025.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), HAEMONETICS CORP's Research And Development Expense has grown by 162.9%.
- Historical annual values: Fiscal year 2025: $62.72 million | Fiscal year 2024: $54.44 million | Fiscal year 2023: $50.13 million | Fiscal year 2022: $46.80 million | Fiscal year 2021: $32.86 million | Fiscal year 2020: $30.88 million | Fiscal year 2019: $35.71 million | Fiscal year 2018: $39.23 million | Fiscal year 2017: $37.56 million | Fiscal year 2016: $44.97 million | Fiscal year 2015: $54.19 million | Fiscal year 2014: $54.20 million | Fiscal year 2013: $44.39 million | Fiscal year 2012: $36.80 million | Fiscal year 2011: $32.66 million | Fiscal year 2010: $26.38 million | Fiscal year 2009: $23.86 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: